clomipramine both increase sedation. Use Caution/Monitor.clobazamclobazam will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. clomipramine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clonazepamclonazepam and clomipramine both increase sedation. Use Caution/Monitor.clorazepateclorazepate and clomipramine both increase sedation. Use Caution/Monitor.clozapineclozapine and clomipramine both increase sedation. Use Caution/Monitor.cobicistatcobicistat will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Carefully titrate antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant responsecobicistat will increase the level or effect of clomipramine by Other (see comment). Use Caution/Monitor. Carefully titrate dose of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitor its response during coadministration with TCAs and cobicistat. cocaine topicalclomipramine and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.codeinecodeine and clomipramine both increase sedation. Use Caution/Monitor.clomipramine decreases effects of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine.conivaptanconivaptan will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.crizotinibcrizotinib and clomipramine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.cyclizinecyclizine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclizine and clomipramine both increase sedation. Use Caution/Monitor.cyclobenzaprinecyclobenzaprine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprine and clomipramine both increase sedation. Use Caution/Monitor.cyclosporinecyclosporine will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cyproheptadinecyproheptadine and clomipramine both increase sedation. Use Caution/Monitor.dantrolenedantrolene and clomipramine both increase sedation. Use Caution/Monitor.daridorexantclomipramine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.darifenacin will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.darifenacin and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.darunavirdarunavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dasatinibclomipramine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.debrisoquineclomipramine decreases effects of debrisoquine by Other (see comment). Use Caution/Monitor. Comment: Inhibition of uptake by adrenergic neurons.deferasiroxdeferasirox increases levels of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.desfluranedesflurane and clomipramine both increase sedation. Use Caution/Monitor.desflurane and clomipramine both increase QTc interval. Use Caution/Monitor.desipramineclomipramine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and desipramine both increase sedation. Use Caution/Monitor.desvenlafaxinedesvenlafaxine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mgdeutetrabenazineclomipramine and deutetrabenazine both increase sedation. Use Caution/Monitor.deutetrabenazine and clomipramine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniraminedexchlorpheniramine and clomipramine both increase sedation. Use Caution/Monitor.dexfenfluramineclomipramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.dexmedetomidinedexmedetomidine and clomipramine both increase sedation. Use Caution/Monitor.dexmethylphenidateclomipramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetamineclomipramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.clomipramine increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor.dextroamphetamine transdermalclomipramine will increase the level or effect of dextroamphetamine transdermal by pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response.dextromoramidedextromoramide and clomipramine both increase sedation. Use Caution/Monitor.diamorphinediamorphine and clomipramine both increase sedation. Use Caution/Monitor.diazepamdiazepam and clomipramine both increase sedation. Use Caution/Monitor.diazepam intranasaldiazepam intranasal, clomipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.dichlorphenamidedichlorphenamide and clomipramine both decrease serum potassium. Use Caution/Monitor.diclofenacclomipramine, diclofenac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.dicyclominedicyclomine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diethylpropionclomipramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalindifelikefalin and clomipramine both increase sedation. Use Caution/Monitor.difenoxin hcldifenoxin hcl and clomipramine both increase sedation. Use Caution/Monitor.diflunisalclomipramine, diflunisal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.dihydroergotamineclomipramine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.dihydroergotamine intranasalclomipramine and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.dimenhydrinatedimenhydrinate and clomipramine both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.diphenhydramine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and clomipramine both increase sedation. Use Caution/Monitor.diphenoxylate hcldiphenoxylate hcl and clomipramine both increase sedation. Use Caution/Monitor.dipipanonedipipanone and clomipramine both increase sedation. Use Caution/Monitor.dobutamineclomipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dolasetronclomipramine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.donepezildonepezil increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil and clomipramine both increase QTc interval. Use Caution/Monitor.dopamineclomipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexamineclomipramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinclomipramine and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and dosulepin both increase sedation. Use Caution/Monitor.doxepinclomipramine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and doxepin both increase sedation. Use Caution/Monitor.doxylaminedoxylamine and clomipramine both increase sedation. Use Caution/Monitor.dronedaronedronedarone will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.droperidoldroperidol and clomipramine both increase sedation. Use Caution/Monitor.echothiophate iodideechothiophate iodide increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.efavirenzefavirenz and clomipramine both increase QTc interval. Use Caution/Monitor.elagolixelagolix will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates.eletriptaneletriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.eliglustateliglustat increases levels of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.eliglustat and clomipramine both increase QTc interval. Use Caution/Monitor.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.entrectinibentrectinib and clomipramine both increase QTc interval. Use Caution/Monitor.epcoritamabepcoritamab, clomipramine. affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Epcoritamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .ephedrineclomipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine increases effects of ephedrine by unknown mechanism. Use Caution/Monitor.epinephrineclomipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine increases effects of epinephrine by unknown mechanism. Use Caution/Monitor.epinephrine inhaledclomipramine and epinephrine inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Tricyclic antidepressants may potentiate epinephrine effect on cardiovascular system.epinephrine racemicclomipramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor.ergotamineclomipramine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.eribulineribulin and clomipramine both increase QTc interval. Use Caution/Monitor.erythromycin baseerythromycin base will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.erythromycin ethylsuccinateerythromycin ethylsuccinate will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.erythromycin lactobionateerythromycin lactobionate will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.erythromycin stearateerythromycin stearate will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.escitalopramescitalopram increases toxicity of clomipramine by QTc interval. Use Caution/Monitor.esketamine intranasalesketamine intranasal, clomipramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.eslicarbazepine acetateeslicarbazepine acetate will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.estazolamestazolam and clomipramine both increase sedation. Use Caution/Monitor.ethanolclomipramine and ethanol both increase sedation. Use Caution/Monitor.etodolacclomipramine, etodolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.etomidateetomidate and clomipramine both increase sedation. Use Caution/Monitor.ezogabineezogabine, clomipramine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fedratinibfedratinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.fedratinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.fenbufenclomipramine, fenbufen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.fenfluramineclomipramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenfluramine, clomipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.fenoprofenclomipramine, fenoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.fesoterodinefesoterodine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.fexinidazolefexinidazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.fexinidazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.fingolimodfingolimod and clomipramine both increase QTc interval. Use Caution/Monitor.flavoxateflavoxate and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.flecainideclomipramine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.fluoxetineclomipramine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazinefluphenazine and clomipramine both increase sedation. Use Caution/Monitor.flurazepamflurazepam and clomipramine both increase sedation. Use Caution/Monitor.flurbiprofenclomipramine, flurbiprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.fluvoxaminefluvoxamine and clomipramine both increase QTc interval. Modify Therapy/Monitor Closely.formoterolclomipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fosamprenavirfosamprenavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fosaprepitantfosaprepitant will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.foscarnetclomipramine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fosphenytoinfosphenytoin will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.frovatriptanfrovatriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.gabapentingabapentin, clomipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilgabapentin enacarbil, clomipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.galantaminegalantamine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.ganaxoloneclomipramine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacingemifloxacin and clomipramine both increase QTc interval. Use Caution/Monitor.gilteritinibgilteritinib and clomipramine both increase QTc interval. Use Caution/Monitor.glofitamabglofitamab, clomipramine. affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Glofitamab